Thursday, 9th February 35th Lorne Cancer Conference 2023

• Tissue Stem Cells and Their Microenvironment: Coping with Oncogenic Stress - Elaine Fuchs
• Oncogenic activities of mutant p53 and Mdm2 - Carol Prives
• Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine - Kendelle J Murphy
• Delineating the molecular and cellular origins of hepatocellular carcinoma using genetic mouse models - Naiyang Fu

• Acute leukemia at the intersection of genomics and cell of origin - Charles Mullighan
• Multi-omic profiling of to identify prognostic markers in oesophageal cancer - Nic Waddell
• Increasing the precision of precision medicine for children with high-risk cancers - Mark Cowley
• Oncogenic mutant p53 proteins are selectively shuttled by cancer extracellular vesicles to educate the tumor microenvironment - Bibek Bhatta
• Determining the essential functions of distinct pro-survival BCL-2 family members by using gene-swap mice - Kerstin Brinkmann
• Desmoglein-2, an unsuspected regulator of tumour vasculature and immune response in melanoma - Michaelia Cockshell
• Identifying novel vulnerabilities to sensitise Lkb1-mutant lung adenocarcinoma to T cell mediated killing   - Jackson A McDonald
• Investigation of novel therapeutic targets in pancreatic cancer-associated fibrosis - Benjamin J McLean
• Targeting the minor spliceosome as a therapeutically viable target for a broad spectrum of cancers - Stephen Mieruszynski
• Dissecting the pleiotropic roles of subcellular c-Jun NH-Terminal Kinase in mammary development and breast cancer progression - Yolande O'Donnell

Includes flash talk presentations. 

Bibek Bhatta
Oncogenic mutant p53 proteins are selectively shuttled by cancer extracellular vesicles to educate the tumor microenvironment abs# 8

Kerstin Brinkmann
Determining the essential functions of distinct pro-survival BCL-2 family members by using gene-swap mice abs# 9

Michaelia Cockshell
Desmoglein-2, an unsuspected regulator of tumour vasculature and immune response in melanoma abs# 10

Miriam Fuentes-Guirado
Restoring Immune Control of Bone-Metastatic Breast Cancer with Type I Interferon Modulators abs# 11

Jackson A McDonald
Identifying novel vulnerabilities to sensitise Lkb1-mutant lung adenocarcinoma to T cell mediated killing abs# 12

Benjamin J McLean
Investigation of novel therapeutic targets in pancreatic cancer-associated fibrosis abs# 13

Stephen Mieruszynski
Targeting the minor spliceosome as a therapeutically viable target for a broad spectrum of cancers abs# 14

Yolande O'Donnell
Dissecting the pleiotropic roles of subcellular c-Jun NH-Terminal Kinase in mammary development and breast cancer progression abs# 15

• Developing and characterising a novel age-appropriate preclinical model for paediatric medulloblastoma - Zahra Abbas
• Understanding the cellular origin of Barrett’s metaplasia and its progression - Ibukun Adejumobi
• The Biology of Melanoma Metastases and Response to Therapy - Veronica Aedo-Lopez
• Characterizing the adaptive starvation response in melanoma cells treated with targeted therapies  - Arwa Alkaraki
• high fat diet modulates efficacy of BRAF/MEK targeted therapy in Melanoma - Shaghayegh Arabi
• Artificial Intelligence derived body composition to accurately predict chemotherapy toxicities following oxaliplatin therapy in colon cancer patients and role of AI-derived body composition - Yasser Arafat
• Inhibiting stromal fibrosis in pancreatic cancer - Sakshi Arora
• p53 isoform expression promotes a stemness phenotype and drives therapy resistance in breast cancer. - Kelly Avery-Kiejda
• Investigating the therapeutic efficacy of EO3001 in clear cell carcinoma of the ovary - Jeffrey Bacha
• Targeting tumour cell-specific MHC-II (tsMHC-II) regulators to enhance anti-tumour immunity in NSCLC - Adithya Balasubramanian
• Drug and CRISPR screening of cell lines and organoids to identify new combination treatments for ovarian carcinosarcoma - Holly E Barker
• Mpl Signalling in Normal Hematopoiesis and Myeloproliferative Neoplasms - Kira Behrens
• Identifying Mesothelioma Prognostic Gene Signature Using Genetically Diverse CC-MexTAg Mouse Model - Kiarash Behrouzfar
• Treatment-induced DNA methylation heterogeneity and implications for cell growth in Acute Myeloid Leukaemia - Danielle Bond
• Elucidating the tumour vasculature to better understand cancer progression - Claudine S Bonder
• Why are they responding? Using immuno-genomics to understand combination PARP inhibitor plus immunotherapy response in high-grade serous ovarian cancer: SOLACE2 - Nirashaa T Bound
• Mutation of the E3 ubiquitin ligase CBL as a mechanism of kinase activation and a potential therapeutic target in paediatric cancer - Lauren M Brown
• Re-purposing Non-oncology Agent Itraconazole To Target The Dynamic Cellular Ecosystem Of Pancreatic Cancer - Diego Chacon-Fajardo
• Beta blockade enhances anthracycline control of metastasis in triple negative breast cancer  - Aeson Chang
• Cell type annotations of single cell spatial transcriptomics CosMx data on NSCLC - Jinjin Chen
• Mechanisms of stromal-induced immunosuppression in triple negative breast cancer - Julia Chen
• Investigating the roles of mutant TP53 in lung adenocarcinoma using novel genetically engineered mouse models - Tianwei Chen
• Time course analysis of pseudo-bulk samples from single cell RNA sequencing data - Jinming Cheng
• Exploiting tumour’s metabolic vulnerability as a therapeutic strategy - Hui Yi Chew
• Cytoplasmic JNK activity promotes metastasis in triple negative breast cancer - Misaki S Clearwater
• A novel Focal Adhesion Kinase inhibitor AMP945 for first-line treatment of pancreatic cancer - Terrie-Anne Cock
• Australian cardio-oncology registry a prospective observational study of patients who have been exposed to cardio-toxic chemotherapy - Lane Collier
• Mammary adipocrine IGFBP2 limits invasive breast cancer progression - James RW Conway
• PRIORITY-P – Real time implementation of pharmacogenomics in paediatric patients with a new cancer diagnosis or those receiving haematopoietic stem cell transplant - Rachel Conyers
• CRISPR activation screens identify co-drivers of malignant haematopoiesis in a DNMT3a mutant background - Amali Cooray
• Novel patient-derived organoids in a rare ovarian cancer: a tool for high-throughput drug screening - Olivia Craig
• Bipolar Androgen Therapy (BAT) inhibits the growth of patient-derived models of advanced prostate cancer - Georgia Cuffe
• Whole genome CRISPR/Cas9 screening to understand resistance to BH3-mimetic drugs in lymphoma - Sarah T Diepstraten
• Understanding cellular mechanisms involved in drug response to gp130/STAT3 inhibitors in combination with chemotherapy in colorectal cancer - Rhynelle Dmello
• Regulation of a novel splice variant of Early Growth Response 4 (EGR4-S) by HER+ signalling and HSF1 in breast cancer - Jeremy M Drake
• Can HE4 replace CA 125 as a diagnostic biomarker in ovarian cancer? - Harshita Dubey
• Expression and function of ADAMTS1 in ovarian cancer progression and chemoresistance - Ruth M Escalona
• Elucidating the oncogenic role of telomere dysfunction in drug resistant ER+ breast cancer - Leila Eshraghi
• A good TIME for cancer immunotherapy - Isabel Everard
• SULF1 is highly expressed at Epithelial Mesenchymal Transition (EMT)/MET state of triple negative breast cancer and is a novel therapeutic target to reduce metastasis of TNBC - Narjis Fatima
• The pan-cancer lncRNA PLANE regulates an alternative splicing program to promote cancer pathogenesis - Yuchen Feng
• RNA Polymerase I inhibitors for cancer therapy - Rita Ferreira
• Multi-substrate metabolic tracing reveals marked heterogeneity and dependency on fatty acid metabolism in human prostate cancer - Gio Fidelito
• Evolving genomic complexity unveiled in ctDNA analysis of melanoma patients - Sandra Fitzgerald
• Spatial transcriptomics reveals ovarian cancer subclones with distinct tumour microenvironments - Alistair Forrest
• Selective androgen receptor modulators in combination with CDK4/6 inhibitors demonstrate anti-cancer activity in preclinical treatment resistant ER+AR+ breast cancer models - Allegra Freelander
• A Phase 1-2 clinical trial of EO1001, a novel irreversible pan-ErbB inhibitor with promising brain penetration - Elizabeth Ahern
• Unravelling the role of neutrophils in pancreatic cancer - Ka Yee Fung
• Linking determination of cell fate in the developing nervous system to diffuse midline glioma - Liam M Furst
• Use of optical barcoding to uncover the mechanisms associated with clonal fate in metastatic breast cancer - Sreeja Gadipally
• A novel aptamer-drug conjugate provides therapeutic potential against Glioblastoma - Breanna Giles
• Targeting Ribosome Biogenesis using the Inhibitor of RNA Polymerase I Transcription CX-5461 in the Treatment of Multiple Myeloma - Kezia Gitareja
• Glypican-1 CAR T-cells as a Novel Immunotherapy for Ovarian Cancer - Lizamarie SB Goonetilleke
• TrajectoryNet reveals temporal transcriptional relationships driving the mesenchymal-to-epithelial transition in tumour formation - Shabarni Gupta
• Characterising epithelial-to-mesenchymal transition in ovarian carcinosarcoma preclinical models to identify new targets for treatment - Anthony Hadla
• Modelling Single Agent Apoptosis to Rationalise Multi-Agent Chemotherapy in High-Risk Neuroblastoma - Jeremy ZR Han
• Understanding the relationship between FOXL2^C134W and SMADs in driving adult granulosa cell tumour pathogenesis - Teharn Hegarty
• Initial biodistribution data of ImmunoPET a Phase 0/1 Study characterising PD-L1 with ⁸⁹Zr- Durvalumab (MEDI4736) PET/CT - Fiona Hegi-Johnson
• Using E-cadherin dynamics and Src activity to predict cancer spread and response to anti-invasive therapies. - David Herrmann
• Cooperativity between Hyaluronan Mediated Motility Receptor (HMMR) and Androgen receptor signalling regulates prostate cancer tumorigenesis. - Josephine Hinneh
• A novel multi-omics immunopeptidomics platform to identify immunogenic neoantigens for precision T-cell receptor therapy for cancer - Gwo Yaw Ho
• Lipid elongation is an emerging mechanism of resistance to CDK4/6 inhibition in prostate cancer - Joshua T Hodgson
• Fractionated radiotherapy is required to accurately mimic neurostructural late effects in preclinical models - Meegan Howlett
• Sensitisation and eradication of chemo-resistant T-ALL by repurposing epigenetic and non-conventional cancer drugs - Jackie Huang
• The role of PU.1 in mediating glucocorticoid response in acute lymphoblastic leukaemia - Jackie Huang
• Defining cancer associated fibroblast states associated with response to checkpoint immunotherapy in the triple negative breast cancer. - Sergio Erdal Irac
• mTORC1 differentially regulates ferroptosis induced by inhibition of GPX4 or SLC7A11 - Thomas Jackson
• Unusual PDGFRB fusion reveals novel mechanism of kinase activation in Ph-like ALL. - Fatimah B. Jalud
• Multi-omics characterisation of breast cancer organoids - Dilys Leung
• Characterising the role of a p53 regulated Huwe1 enhancer in Eμ-Myc lymphomagenesis - Wei Jin
• The role of UBF in malignant transformation - Vrinda Johri
• Ex vivo culture of nsclc and healthy lung tissue - Daniel Batey